Björn Mulder: Differentiating PRP Formulations and Cell Counts in Knee and Ankle OA
Björn Mulder, Medical Doctor at DokterMulder.nl, shared a post on LinkedIn:
“PubMed Wrapped – September 2026 – Orthobiologics
PRP vs HA in knee OA – two meta-analyses, two verdicts (J ISAKOS / Arthroscopy)
Alshehri: 28 RCTs, 2,685 pts. PRP beats HA on WOMAC (MD −8.1). Larger effect with leukocyte-poor PRP, multiple injections, KL I–II.
Zhong: 21 RCTs, 1,790 pts. PRP separates from HA only at 12 months. Larger effect with leukocyte-rich, activated PRP.
Platelet dose: neither reports it. Proxies only, and they disagree.
Platelet volume, density and the homeostatic blueprint (J Clin Med)
Everts, Podesta, Sánchez, Harrison et al. Review plus original data, 389 patients.
Platelets are not one population: density spans 1.040–1.091 g/mL, and the dense, high-MPV, alpha-granule-rich ones sediment with the buffy coat and red cells. PRP-MPV correlated with residual RBC (r = 0.50).
Clear-yellow single-spin PRP leaves exactly those platelets in the tube.
Platelet dose: double-spin averaged 2,082 × 10³/µL; MPV rose 7.55 → 8.4 fL. Threshold: ≥1 × 10⁹/mL.
Intraosseous BMC in bilateral ankle OA – 15-year contralateral-controlled (Medicina)
Hernigou, Centeno et al. 88 patients, one ankle treated, one observed. Fusion or arthroplasty: 18% vs 50%. HR 0.24.
Cell dose: HR 0.70 per 10,000 CFU-F. A real dose-response.
PRP vs hydrolyzed type I collagen vs HA in knee OA – RCT (Future Sci OA)
135 pts, KL 2–3, three US-guided injections. HA wins at one month; PRP and collagen hold better to six.
Dose: schedule defined, PRP composition not reported.
PRP and HA vs HA alone in knee OA – 150 knees, 12 months (J Exp Orthop)
Totlis et al. Three injections each arm, KL II–IV. Combination beat HA alone on VAS, KOOS and EQ-5D at 6 and 12 months, and on PASS/MCID responders.
Platelet dose: PRP characterised and reported under DEPA (CCA). HA 20 mg/2 mL, 2.8–3.2 MDa.
Not randomised.
But the only knee study this month that says what was in the syringe.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series